Engineered T-Cells take on tough blood cancers in first human trial
Disease control
Recruiting now
This early-phase study tests a new treatment called CER-1236 for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis) that have not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified…
Phase: PHASE1 • Sponsor: CERo Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC